Physician profile
Vanessa Eileen Beard-Ely
NPI 1730140484
$79,829.82
in general payments reported to CMS, 2019-2025
41 companies · $1,375 in 2025
The $1,375 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36K · 2022: $11K · 2023: $17K · 2024: $15K · 2025: $1,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $6,719 · Travel and Lodging: $1,757 · Education: $41.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,140.00 |
| Food and Beverage | $6,719.23 |
| Travel and Lodging | $1,756.69 |
| Education | $41.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $34,866.92 | 2021 | |
| Abbvie INC. | $22,837.74 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $8,619.67 | 2022 | |
| Pfizer INC. | $4,336.26 | 2023-2024 | |
| Medtronic, INC. | $2,182.95 | 2021-2025 | Percept PC Brainsense, Sensight |
| Teva Pharmaceuticals USA, INC. | $1,556.94 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Sk Life Science, INC. | $1,274.08 | 2021-2025 | |
| Boston Scientific Corporation | $1,144.06 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $369.93 | 2021-2024 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $320.62 | 2021-2024 | Nuplazid |
| Celgene Corporation | $298.52 | 2021-2024 | Zeposia |
| Abbott Laboratories | $257.31 | 2021-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $234.07 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $227.15 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $152.98 | 2023 | Soliris, Ultomiris |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $144.55 | 2021-2025 | Gocovri, Gocovri |
| Ani Pharmaceuticals, INC. | $127.25 | 2023 | Purified Cortrophin Gel |
| Livanova USA, INC. | $120.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $100.46 | 2021-2022 | |
| Argenx US, INC. | $88.09 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $60.35 | 2024 | Amyvid |
| Amgen INC. | $58.91 | 2021-2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $58.85 | 2021-2025 | Crexont |
| Ucb, INC. | $45.59 | 2024-2025 | Rystiggo |
| Mallinckrodt Hospital Products INC. | $37.56 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $33.44 | 2024 | |
| Impel Pharmaceuticals INC. | $31.37 | 2023 | Trudhesa |
| Tg Therapeutics, INC. | $30.82 | 2023-2024 | |
| Lundbeck LLC | $26.53 | 2024 | Vyepti |
| Eisai INC. | $21.67 | 2024 | |
| Csl Behring | $19.46 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.53 | 2023 | Keveyis |
| Zogenix INC. | $17.56 | 2021 | |
| Averitas Pharma INC. | $16.52 | 2023 | Qutenza |
| Arbor Pharmaceuticals, INC. | $16.31 | 2022 | |
| Grifols USA, LLC | $16.07 | 2023 | Gamunex-C |
| Ge Healthcare | $14.44 | 2024 | |
| Azurity Pharmaceuticals, INC. | $13.62 | 2023 | Horizant |
| Genzyme Corporation | $13.17 | 2022 | |
| Sumitomo Pharma America, INC. | $13.06 | 2023 | Aptiom |
| Genentech USA, INC. | $6.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Beard-Ely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.